Oral Orforglipron Sustains Weight Loss After Injectable GLP-1 Therapy

Incretin-based therapies have reshaped obesity management, but the field has largely sidestepped a practical question: what happens when patients cannot or will not continue injecting? Cost, supply constraints, needle aversion, and access in lower-resource settings all limit long-term adherence to injectables. Orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, has previously demonstrated weight loss efficacy and cardiometabolic improvements with a safety profile broadly similar to injectable agents.¹ ATTAIN-MAINTAIN is the first phase 3b trial to test whether it can function as a maintenance bridge after injectable therapy is withdrawn.¹

The global prevalence of obesity has steadily increased over the past decades, posing a significant public health challenge. According to the World Health Organization, over 1 billion people worldwide are obese, a number projected to rise. Obesity is a complex chronic disease associated with numerous comorbidities, including type 2 diabetes, cardiovascular disease, certain cancers, and musculoskeletal disorders. Sustained weight loss is crucial for mitigating these health risks. While lifestyle interventions remain foundational, pharmacological treatments, particularly GLP-1 receptor agonists, have emerged as highly effective tools for achieving clinically meaningful weight reduction. However, the long-term nature of obesity management necessitates therapies that are not only effective but also sustainable and accessible for diverse patient populations. The development of oral GLP-1 receptor agonists addresses a critical unmet need by offering an alternative to injectable formulations, potentially improving patient convenience and adherence, especially for individuals who experience discomfort or inconvenience with injections. Orforglipron, as a nonpeptide oral agent, represents a distinct pharmacological approach compared to peptide-based injectables, offering potential advantages in manufacturing and stability. Its mechanism of action involves binding to and activating the GLP-1 receptor, leading to glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and increased satiety, all contributing to weight loss.

The trial

ATTAIN-MAINTAIN was a double-blind, placebo-controlled, randomised trial that enrolled participants from the SURMOUNT-5 study who had previously received either tirzepatide or semaglutide and reached a body weight plateau on those agents.¹ Two cohorts were enrolled: cohort 1 comprised 205 participants previously treated with tirzepatide, and cohort 2 comprised 171 participants previously treated with semaglutide.¹ Within each cohort, participants were randomised to receive orforglipron once daily or placebo for 52 weeks.¹ The primary endpoint was the model-based estimate (MBE) of the percentage of prior body weight reduction maintained at week 52, assessed using the treatment-regimen estimand.¹

Participants were required to have achieved a stable weight loss on their prior injectable GLP-1 therapy, defined as a plateau where further significant weight reduction was not observed over a specified period. This ensured that the trial evaluated the maintenance phase rather than initial weight loss induction. Randomisation was stratified by prior injectable therapy (tirzepatide or semaglutide) to ensure balanced groups within each cohort. The dose of orforglipron was titrated over several weeks to reach a maximum tolerated dose, consistent with the titration schedules used for other GLP-1 receptor agonists to mitigate gastrointestinal side effects. Placebo was administered orally once daily, matching the appearance of orforglipron to maintain blinding. The treatment-regimen estimand for the primary endpoint accounted for treatment discontinuation, ensuring that the analysis reflected the real-world effectiveness of the assigned treatment strategy. Secondary endpoints included changes in body weight from randomisation, proportion of participants maintaining at least 75% of prior weight loss, and changes in cardiometabolic parameters such as blood pressure, lipid profiles, and glycemic markers. Safety assessments included monitoring of adverse events, vital signs, and laboratory parameters throughout the 52-week study period.

In cohort 1, participants on orforglipron maintained an MBE of 74.7% (s.e.m. 4.05) of their prior weight reduction, compared with 49.2% (s.e.m. 3.92) in the placebo group, an estimated treatment difference of 25.5 percentage points (95% CI 14.5 to 36.5; P less than 0.001).¹ In cohort 2, the separation was larger: orforglipron maintained an MBE of 79.3% (s.e.m. 4.42) versus 37.6% (s.e.m. 7.46) with placebo, yielding a treatment difference of 41.7 percentage points (95% CI 24.4 to 59.0; P less than 0.001).¹ All key secondary endpoints were met in both cohorts.¹ The most common adverse events were gastrointestinal in nature, characterised as mostly mild to moderate in severity, consistent with the known GLP-1 receptor agonist class effect.¹

The trial carries two limitations the authors identify directly. First, there was no comparator arm in which participants continued their original injectable therapy, so ATTAIN-MAINTAIN cannot quantify the gap between oral maintenance and uninterrupted injection-based treatment.¹ This absence means the trial cannot definitively establish whether switching to oral orforglipron is non-inferior or superior to continuing the original injectable therapy for weight maintenance. Future research could address this by including an active comparator arm. Second, the follow-up period was limited to one year, leaving durability beyond 52 weeks uncharacterised.¹ Long-term data, extending beyond one year, are crucial for understanding the sustained efficacy and safety of orforglipron as a maintenance therapy, particularly given the chronic nature of obesity. The higher treatment difference observed in the semaglutide cohort warrants some interpretive caution: the placebo group in cohort 2 showed a notably larger weight regain (MBE 37.6% maintenance versus 49.2% in cohort 1), which amplifies the between-arm difference arithmetically and may partly reflect cohort-level differences in baseline characteristics or the differential weight-loss profiles of semaglutide versus tirzepatide rather than a true pharmacological advantage of orforglipron in this subgroup.¹ For instance, participants in cohort 2 might have had a higher baseline BMI or different metabolic profiles that predisposed them to greater weight regain upon placebo withdrawal, thus artificially inflating the observed treatment effect of orforglipron in that specific cohort. Further subgroup analyses or trials designed to directly compare maintenance strategies after different initial injectable therapies could help elucidate these potential differences.